Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.

Poseida Therapeutics, Inc.

Poseida Therapeutics is a clinical-stage biopharmaceutical company advancing differentiated cell and gene therapies with the capacity to cure certain cancers and rare diseases. The Company's pipeline includes allogeneic CAR-T cell therapy product candidates for both solid and liquid tumors as well as in vivo gene therapy product candidates that address patient populations with high unmet medical need. The Company's approach to cell and gene therapies is based on its proprietary genetic editing platforms, including its non-viral piggyBac® DNA Delivery System, Cas-CLOVER™ Site-Specific Gene Editing System and nanoparticle and hybrid gene delivery technologies as well as in-house cell therapy manufacturing. The Company has formed a global strategic collaboration with Roche to unlock the promise of cell therapies for patients with hematological malignancies. Learn more at www.poseida.com.

	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	9.77M -	2.98M 69.44%				31.24K -	130.36M 417,217.08%	64.70M 50.37%
cost of revenue				1.19M -	2.59M 116.76%	4.55M 76.02%	5.17M 13.62%
gross profit	9.77M -	2.98M 69.44%		-1.19M -	-2.59M 116.76%	-4.52M 74.82%	125.19M 2,869.21%	64.70M 48.32%
selling and marketing expenses	-220K -
general and administrative expenses	5.35M -	5.48M 2.35%	9.67M 76.57%	18.46M 90.79%	23.03K 99.88%	35.91K 55.96%	37.54M 104,421.79%	37.44M 0.28%
selling general and administrative expenses	5.13M -	5.48M 6.74%	9.67M 76.57%	18.46M 90.79%	23.03K 99.88%	35.91K 55.96%	37.54M 104,421.79%	37.44M 0.28%
research and development expenses	9.86M -	19.10M 93.62%	30.88M 61.70%	60.39M 95.55%	103.52K 99.83%	136.73K 32.08%	152.90M 111,722.22%	156.77M 2.53%
other expenses		37K -	-821K 2,318.92%	2.56M 411.69%	280 99.99%	19.80K 6,969.64%	2.86M 14,337.99%
cost and expenses	15.22M -	24.58M 61.52%	40.56M 65.01%	78.85M 94.42%	126.55K 99.84%	172.65K 36.43%	190.44M 110,203.56%	194.21M 1.98%
operating expenses	15.00M -	24.58M 63.89%	40.56M 65.01%	78.85M 94.42%	126.55K 99.84%	172.65K 36.43%	190.44M 110,203.56%	194.21M 1.98%
interest expense		558K -	1.80M 221.86%	3.55M 97.83%	3.51K 99.90%	3.36K 4.22%	6.37M 189,596.25%	-8.67M 236.12%
ebitda	-5.23M -	-20.88M 299.31%	-40.69M 94.87%	-75.10M 84.57%	-126.27K 99.83%	-121.62K 3.68%	-57.09M 46,841.19%	-129.50M 126.85%
operating income	-5.45M -	-19.67M 260.95%	-41.99M 113.49%	-85.53M 103.70%	-126.55K 99.85%	-141.41K 11.74%	-59.95M 42,291.33%	-129.50M 116.03%
depreciation and amortization	220K -	676K 207.27%	689K 1.92%	10.44M 1,414.51%	280 100.00%	19.80K 6,969.64%	2.86M 14,337.99%
total other income expenses net	109K -	1.96M 1,700%	-2.25M 214.83%	-994K 55.88%	-3.23K 99.68%	16.44K 609.52%	-3.51M 21,466.43%	6.18M 276.00%
income before tax	-5.34M -	-20.19M 278.07%	-44.61M 120.94%	-86.53M 93.98%	-129.78K 99.85%	-124.97K 3.70%	-63.46M 50,676.96%	-123.32M 94.34%
income tax expense	-765K -	-527K 31.11%	-202K 61.67%	6.11M 3,125.74%	-2.58M 142.25%	-4.53M 75.39%	544K 112.01%	-107K 119.67%
net income	-4.58M -	-19.66M 329.77%	-44.40M 125.84%	-92.64M 108.63%	2.45M 102.65%	4.40M 79.57%	-64.00M 1,553.31%	-123.43M 92.85%
weighted average shs out	59.32M -	39.73M 33.01%	35.93M 9.57%	39.73M 10.59%	36.00M 9.40%	62.18M 72.73%	71.91M 15.66%	90.19B 125,309.73%
weighted average shs out dil	59.32M -	39.73M 33.01%	35.93M 9.57%	39.73M 10.59%	36.00M 9.40%	62.24M 72.89%	71.95M 15.61%	90.19B 125,237.67%
eps	-0.08 -	-0.49 535.54%	-1.24 153.06%	-2.33 87.90%	0.07 102.92%	0.07 3.96%	-0.89 1,357.06%	-0.00 99.84%
epsdiluted	-0.08 -	-0.49 535.54%	-1.24 153.06%	-2.33 87.90%	0.07 102.92%	0.07 3.96%	-0.89 1,357.06%	-0.00 99.84%

COM:POSEIDA

Poseida Therapeutics, Inc.

Last Close

2.93

08/11 21:00

Market Cap

288.93M

Beta: -

Volume Today

1.24M

Avg: -

Preview